Parmantier sets EUR 20.50 target for Evonik stock

Published on 10/19/2026 at 10:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik stock costs EUR 21.42 on October 19, 2026 versus its Xetra close. Third-quarter results are due November 3, 2026. Market value is EUR 10.0 billion.

Analyst target and earnings dates

Parmantier set a EUR 20.50 six-month target for Evonik on October 6, 2026.
Evonik reported EUR 3.9 billion in second-quarter revenue, up 11.00 percent year over year.
Evonik stock traded at EUR 21.42 at 10:06 a.m. CEST at Lang & Schwarz on October 19, 2026, unchanged versus the Xetra close of October 16, 2026.

Schwarzweiß-Reportagebild von Industriearbeitern bei der Inspektion chemischer Reaktorbehälter — Evonik Industries DE000EVNK013 in einer dokumentarischen Schwarzweiß-Reportage von Arbeitern an industriellen Chemikalienbehältern, Illustration mit AI erstellt.

Evonik (ISIN DE000EVNK013) carries a six-month target of EUR 20.50 from Parmantier & Cie., which rated the stock Hold on October 6, 2026, according to Boersen-Zeitung. At 10:06 a.m. CEST on October 19, 2026, the stock was at EUR 21.42 at Lang & Schwarz, unchanged versus the Xetra close of October 16, 2026.

Why the target matters

The target is 4.29 percent below the Lang & Schwarz price. Parmantier's report described the BASF-Evonik situation as a catalyst but stressed that the approach was non-binding and did not represent an agreed transaction, according to Boersen-Zeitung. That distinction leaves the operating figures as the next test of value.

Three dated developments

On August 4, 2026, Evonik reported second-quarter revenue of EUR 3.9 billion, up 11.00 percent year over year, while adjusted EBITDA rose 24.00 percent to EUR 630.0 million, according to NadirAlpha. On September 25, 2026, Evonik confirmed receipt of a non-binding approach aimed at a voluntary public offer, according to Peptide and Protein. On October 6, 2026, Parmantier published its EUR 20.50 target and Hold rating, as reported by Boersen-Zeitung.

What comes next for earnings

Evonik's second-quarter adjusted EBITDA margin was 16.20 percent, compared with 14.50 percent a year earlier, while free cash flow reached EUR 49.0 million versus negative EUR 211.0 million in the second quarter of 2025, according to NadirAlpha. The improvement is substantial, but the target below the market price shows that analysts are separating temporary earnings support from durable recovery.

Upcoming reporting dates

Evonik's next reporting date is November 3, 2026, for the third quarter of 2026, followed by fourth-quarter reporting on March 4, 2027, according to the company's Evonik investor calendar.

Stock price and valuation

Evonik's market capitalization was EUR 10.0 billion on October 19, 2026. The 52-week range was EUR 12.49 to EUR 21.84, putting the current quote EUR 0.42 below the high.

Evonik stock was trading at EUR 21.42 at Lang & Schwarz on October 19, 2026 at 10:06 a.m. CEST, unchanged versus the Xetra close of October 16, 2026 at EUR 21.42. The further course of trading is shown by the continuously updated real-time quote of Evonik stock.